Physician profile
Fred M Heaton
NPI 1720039027
$2,029.26
in general payments reported to CMS, 2019-2025
24 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $156 · 2021: $344 · 2022: $349 · 2023: $327 · 2024: $282 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $367.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $285.44 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $242.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $160.18 | 2019-2025 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $143.33 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $97.50 | 2020-2025 | Eliquis, Camzyos |
| Pfizer INC. | $92.38 | 2021-2024 | |
| Exact Sciences Corporation | $80.91 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $78.58 | 2019-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $59.77 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.73 | 2023-2025 | Jardiance |
| Urovant Sciences INC | $46.05 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.84 | 2022 | |
| Merck Sharp & Dohme LLC | $37.25 | 2020-2021 | |
| Astellas Pharma US INC | $35.07 | 2019-2023 | Myrbetriq |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $34.09 | 2021 | |
| Abbott Laboratories | $31.96 | 2023-2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.63 | 2025 | Xifaxan |
| Amarin Pharma, INC. | $26.28 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $23.15 | 2025 | Voquezna |
| Sunovion Pharmaceuticals INC. | $19.98 | 2019 | |
| Sanofi Pasteur INC. | $15.47 | 2019 | |
| Seqirus USA INC | $13.98 | 2025 | Flucelvax, Fluad |
| Biohaven Pharmaceutical Holding Company LTD. | $12.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Heaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.